Dual Glucagon and GLP-1 Agonists: Review

A 2026 narrative review argues that combining glucagon-receptor and GLP-1-receptor signaling may offer a useful research direction for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its evidence ladder is uneven: animal models support several metabolic effects, and early clinical trials report encouraging changes, but definitive head-to-head studies against GLP-1-only medicines have not established superiority^[1]. This is a translational review, not a new randomized trial.

What the dual-agonist review covered

The paper focused on compounds designed to activate both the glucagon receptor and the GLP-1 receptor. The authors framed glucagon as more than a glucose-raising hormone, discussing its roles in energy balance and liver metabolism. They paired that rationale with the established glucose-lowering and appetite-related effects of GLP-1 signaling^[2]. The review then followed the concept from preclinical work into early and later clinical development.

This distinction from current single-receptor therapy is important. Semaglutide is a GLP-1 receptor agonist, while the compounds at the center of this review also activate the glucagon receptor. The review cited semaglutide as an example of an effective obesity medicine, not as proof that adding glucagon activity will improve outcomes^[2]. A plausible combination still needs comparative testing.

Why combine glucagon with GLP-1 signaling

Glucagon signaling can increase glucose, which creates an obvious therapeutic tension. The dual-agonist approach attempts to balance that effect with GLP-1 receptor activity, which can support glucose control and reduce food intake. In animal models of obesity and MASH, the review reports that dual agonists reduced food intake and hepatic fat while increasing energy expenditure^[2]. Animal outcomes establish biological activity, but they do not predict the size or durability of benefit in people.

The balance between the two receptor activities may matter as much as the fact that both are present. According to the abstract, glycemic control worsened with some dual agonists, even while other metabolic effects looked favorable^[1]. The compounds are not interchangeable. Molecular design, exposure and receptor balance can produce different clinical profiles, so favorable findings for one candidate cannot establish the effects of another.

What the human evidence suggests

The review states that some early clinical trials produced substantial reductions in body weight and hepatic steatosis, with reports of improvement in hepatic fibrosis as well^[2]. The evidence is not uniform. Those statements summarize several development programs rather than one trial, and readers should not combine them into a single effect estimate or assume that every change was measured with the same method and timeframe.

The authors highlighted mazdutide and survodutide as the most clinically advanced examples at the time of writing. Mazdutide had approval in China for chronic weight management and type 2 diabetes. Survodutide was in global phase 3 trials, with earlier evidence of effects on weight, glucose and liver-health measures in people with MASH^[2]. Regulatory status and evidence maturity therefore differed between the two programs.

MASH findings need disease-specific interpretation

MASH is a progressive liver disease, so weight loss or reduced liver fat does not automatically establish an effect on inflammation, fibrosis progression or long-term clinical outcomes. The review presents dual agonism as a strategy that may affect several parts of the metabolic disease process. Each liver endpoint still needs to be read according to how it was measured and how long participants were followed^[1].

The same caution applies when comparing an investigational dual agonist with established semaglutide research. Cross-trial comparisons can be distorted by different entry criteria, baseline disease severity and outcome definitions. That question remains unresolved in people. The review says directly that whether dual agonists outperform GLP-1 receptor mono-agonists remains to be established in definitive head-to-head studies^[2].

What this review can and cannot establish

As a narrative review with a translational focus, the paper connects physiology, animal experiments and clinical development. That is useful for understanding why the drug class is being pursued. It does not supply a preregistered systematic-review protocol, a pooled estimate or a new randomized comparison. The abstract also does not provide enough detail to independently assess every cited trial's attrition, adverse events or risk of bias^[2].

The paper's positive translational framing should therefore be read as an expert synthesis rather than a treatment recommendation. A reader cannot use it to select a product, infer an appropriate dose or predict a personal liver response. Anyone making decisions about obesity, diabetes or liver disease needs individualized care, including review of approved indications and the evidence for the specific medicine under consideration. See our semaglutide safety overview for separate, medicine-specific context.

What we don't yet know

Definitive evidence has not shown whether glucagon and GLP-1 dual agonists produce better long-term outcomes than GLP-1-only therapy. The best receptor balance is unresolved, and results from one dual agonist may not transfer to another. Questions also remain about durability, tolerability, glycemic effects and whether changes in liver markers translate into fewer cases of cirrhosis or other clinical complications.

The review supports a measured conclusion. Dual glucagon and GLP-1 agonism has moved beyond a laboratory concept, with advanced clinical programs and encouraging early signals. The strategy is not yet validated as a generally superior replacement for GLP-1 receptor mono-agonists. Ongoing phase 3 trials and direct comparisons will determine how much the second receptor target adds.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.